Anti-integrin α(v) therapy improves cardiac fibrosis after myocardial infarction by blunting cardiac PW1(+) stromal cells
dc.rights.license | open | en_US |
dc.contributor.author | BOUVET, M. | |
dc.contributor.author | CLAUDE, O. | |
dc.contributor.author | ROUX, M. | |
dc.contributor.author | SKELLY, D. | |
dc.contributor.author | MASURKAR, N. | |
dc.contributor.author | MOUGENOT, N. | |
dc.contributor.author | NADAUD, S. | |
dc.contributor.author | BLANC, C. | |
dc.contributor.author | DELACROIX, C. | |
dc.contributor.author | CHARDONNET, S. | |
dc.contributor.author | PIONNEAU, C. | |
dc.contributor.author | PERRET, C. | |
dc.contributor.author | YANIZ-GALENDE, E. | |
dc.contributor.author | ROSENTHAL, N. | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | TREGOUET, David-Alexandre | |
dc.contributor.author | MARAZZI, G. | |
dc.contributor.author | SILVESTRE, J. S. | |
dc.contributor.author | SASSOON, D. | |
dc.contributor.author | HULOT, J. S. | |
dc.date.accessioned | 2021-01-18T11:17:35Z | |
dc.date.available | 2021-01-18T11:17:35Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 2045-2322 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/25815 | |
dc.description.abstractEn | There is currently no therapy to limit the development of cardiac fibrosis and consequent heart failure. We have recently shown that cardiac fibrosis post-myocardial infarction (MI) can be regulated by resident cardiac cells with a fibrogenic signature and identified by the expression of PW1 (Peg3). Here we identify αV-integrin (CD51) as an essential regulator of cardiac PW1+ cells fibrogenic behavior. We used transcriptomic and proteomic approaches to identify specific cell-surface markers for cardiac PW1+ cells and found that αV-integrin (CD51) was expressed in almost all cardiac PW1+ cells (93% ± 1%), predominantly as the αVβ1 complex. αV-integrin is a subunit member of the integrin family of cell adhesion receptors and was found to activate complex of latent transforming growth factor beta (TGFβ at the surface of cardiac PW1+ cells. Pharmacological inhibition of αV-integrin reduced the profibrotic action of cardiac PW1+CD51+ cells and was associated with improved cardiac function and animal survival following MI coupled with a reduced infarct size and fibrotic lesion. These data identify a targetable pathway that regulates cardiac fibrosis in response to an ischemic injury and demonstrate that pharmacological inhibition of αV-integrin could reduce pathological outcomes following cardiac ischemia. | |
dc.language.iso | EN | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.subject | VINTAGE | |
dc.title.en | Anti-integrin α(v) therapy improves cardiac fibrosis after myocardial infarction by blunting cardiac PW1(+) stromal cells | |
dc.title.alternative | Sci Rep | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1038/s41598-020-68223-8 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 32647159 | en_US |
bordeaux.journal | Sci Rep | en_US |
bordeaux.page | 11404 | en_US |
bordeaux.volume | 10 | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.issue | 1 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.team | VINTAGE | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.export | false | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Sci%20Rep&rft.date=2020&rft.volume=10&rft.issue=1&rft.spage=11404&rft.epage=11404&rft.eissn=2045-2322&rft.issn=2045-2322&rft.au=BOUVET,%20M.&CLAUDE,%20O.&ROUX,%20M.&SKELLY,%20D.&MASURKAR,%20N.&rft.genre=article |